(R)-3-Cyclopentyl-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazol-1-yl)propanenitrile, 95+%, 250mg

ethyl 5-(3-methoxyphenyl)-1H-pyrazole-4-carboxylate, 95.0%, 5g

3-(2-methylphenyl)piperidine, 95.0%, 5g

2-Bromo-3-ethoxypyridine, 97%, 1g

N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-L-cyclohexylglycine>98.0%(HPLC)(T)5g

N-(4-Fluorobenzyl)-2-((R)-5-(3-methylureido)-2',4'-dioxo-2,3-dihydrospiro[indene-1,5'-oxazolidin]-3'-yl)-N-((S)-1,1,1-trifluoropropan-2-yl)acetamide, 97.0%, 25mg

ethyl 11-oxo-2,3,6,7-tetrahydro-1H,5H,11H-pyrano[2,3-f]pyrido[3,2,1-ij]quinoline-10-carboxylate, 95.0%, 250mg

Disposable samplers ViscoDispo for liquids, Non-sterile, 200 ml, 1000 mm, 10 pieces

5-bromo-1-methyl-3-(trifluoromethyl)-1H-1,2,4-triazole, 95.0%, 10g

6-Bromo-1,4-dihydro-2H-3,1-benzoxazin-2-one, 95.0%, 25g

(2,6-Dibromopyridin-3-yl)boronic acid, 95.0%, 1g

1-(4-bromobenzyl)pyrrolidine hydrochloride, 95.0%, 250mg

Cyclobutane-1,2,3,4-tetracarboxylic dianhydride, 95.0%, 25g